Imperial college How to make it in Africa :Opportunities for Corporate venturing funds by @Sobedih

How to make it in Africa: Pitfalls, challenges,

investment opportunities and success stories

© Imperial College Business School @Sobedih @SobekV

Best Practice Series 2014

1

© Imperial College Business School

@Sobedih @SobekV

Best Practice Series 2014

2

How to make it in Africa: Pitfalls, challenges,

investment opportunities and success stories

© Imperial College Business School @Sobedih @SobekV 3

How to make it in Africa

• Sean Ndiho Obedih

• Open Innovation and Corporate Venture capital in Africa.

• Video

• Talent

• Deal sizes/Dominant players

• Exits

• Success stories

• Opportunities.

11 February 2014 My story so far

© Imperial College Business School

@Sobedih @SobekV

How to make it in Africa

4

© Imperial College Business School

@Sobedih @SobekV 5

How to make it in Africa

Talent

© Imperial College Business School

@Sobedih @SobekV 6

How to make it in Africa

Exits: Financial

services was the

most active exit

sector (23%), but

other sectors such

as food and

beverage (9%) and

telecommunications

(8%) also made

good showings,

illustrating the rise

of the African

consumer.

© Imperial College Business School

@Sobedih @SobekV 7

How to make it in Africa

Most active CVC firms.

© Imperial College Business School

@Sobedih @SobekV 8

How to make it in Africa

• MPESA/VODAFONE (Kenya)

• Spotted in 2002,tried in 2004 and Launched in 2007 with

£1M funding from Vodafone&DFID

• Now in Africa, India and Afghanistan

© Imperial College Business School

@Sobedih @SobekV 9

How to make it in Africa

• Aspen/GSK

• In 2009, GSK took a 16 per cent stake in Aspen,

• granting it the right to distribute GSK products in sub-Saharan Africa. GSK also

handed over a German manufacturing facility along with marketing rights to eight

international products.

• In 2010 Aspen took control of a GSK generic drugs unit in Australia,

• In October it bought a GSK plant in France and thrombosis treatments Arixtra

(fondaparinux sodium) and Fraxiparine (nadroparin) in a deal valued at $1.1bn.

• Those deals and others such as an alliance with Merck & Co helped Aspen become

Africa’s biggest drug maker with 6,000 employees and sales of around $1.9bn in the

year ended June 30 2013, up 27 per cent year-on-year.

• It now says it is the ninth-largest generic drug maker in the world.

• GSK, recently sold 28.2 million shares in Aspen, netting around £425m ($741m).

© Imperial College Business School

@Sobedih @SobekV 10

How to make it in Africa

Opportunities: Africa now has more mobile subscribers

than the US or EU

© Imperial College Business School

@Sobedih @SobekV 11

How to make it in Africa

Informa UK’s terrific Africa Telecoms Outlook projects 334

million African smartphone connections by 2017.

© Imperial College Business School

@Sobedih @SobekV

How to make it in Africa

12

Sean@sobekventures.com

Contact Details:

© Imperial College Business School

@Sobedih @SobekV 13